Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: The experience at children's memorial hospital

Yasmin C Gosiengfiao, Jennifer L Reichek, Jill Woodman, Tamar Ben-Ami, David O Walterhouse*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

It remains unclear how to optimally incorporate gemcitabine and docetaxel into the management of patients with recurrent osteosarcoma. We describe 4 pediatric patients with recurrent osteosarcoma who were treated with gemcitabine±docetaxel and resection. One patient had a partial response and 2 had stable disease. Two patients subsequently underwent surgical resections. Median duration of response was 8 months and was longer for patients who underwent resection. One patient remains disease-free 57 months from recurrence. Our limited series provides additional support for the use of gemcitabine±docetaxel for recurrent osteosarcoma and suggests benefit of concurrent local control measures if possible.

Original languageEnglish (US)
JournalJournal of Pediatric Hematology/Oncology
Volume34
Issue number2
DOIs
StatePublished - Mar 1 2012

Keywords

  • gemcitabine
  • osteosarcoma
  • pediatric
  • recurrent
  • refractory

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: The experience at children's memorial hospital'. Together they form a unique fingerprint.

Cite this